CXCL10 and disease arising from reactivation of latent virus: Both anti-IP-10 mAb (AD8: P=0.016; NL4-3: P=0.031) and CXCR3 antagonist (AD8: P=0.031; NL4-3: P=0.031) abrogated the IP-10-mediated enhancement of HIV latent infection (Figure 2C).